Post-translational modifications (PTMs) substantially broaden the range of function of a given set of proteins, and their identification, as well as understanding their regulation, is of significant research interest. However, due to the challenge of recognizing a small moiety with high affinity, as well as the necessity to recognize small but important differences between modifications and the associated danger of cross reactivity, developing antibodies against PTMs is a complex task. The process becomes even more challenging when the general recognition of a PTM independent of the protein sequence is required.
AMPylation, which has been described in the context of bacterial infection as well as protein homeostasis in the past, is a PTM where reliable antibodies could significantly expand the understanding of its role in signal transduction. This webinar will focus on the development of monoclonal anti-AMP antibodies in mice, recently published in iScience. The design of the synthetic AMPylated peptide for immunization, the selection process to ensure specific binding and backbone-independent recognition, as well as the characterization of lead antibodies and their potential for the future will be discussed.
Register for this webinar to hear about the development of monoclonal anti-AMP antibodies in detail.
Dorothea Höpfner, Doctoral Candidate in the Department of Chemistry, Technical University of Munich
Dorothea Höpfner studied Molecular Biotechnology (B.Sc.) and Biochemistry (M.Sc.) at TU Munich, Germany, which included an international internship at Bayer HealthCare LLC in Biologics Research, in San Francisco, USA. She is currently a doctoral candidate at TU Munich, focusing on AMPylation in the context of bacterial infection in the lab of Aymelt Itzen in the Department of Biochemistry and Signal Transduction UKE, Germany. Her work is supported by the Konrad Adenauer Foundation.Message Presenter
Who Should Attend?
- Directors/Managers in Biopharma or Biotechnology
What You Will Learn
- The challenges of developing sequence-independent anti-PTM antibodies
- Strategy for development of monoclonal anti-AMP antibodies by immunization with a synthetic peptide
- Anti-AMP antibody characterization and their potential for the future
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody services. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early-stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.